Acute tumor lysis syndrome: a comprehensive review - PubMed (original) (raw)
[Article in English, Portuguese]
Affiliations
- PMID: 25307096
Acute tumor lysis syndrome: a comprehensive review
[Article in English, Portuguese]
Michael Darmon et al. Rev Bras Ter Intensiva. 2008 Sep.
Abstract
Tumor lysis syndrome is characterized by the massive destruction of malignant cells and the release in the extra-cellular space of their content. While Tumor lysis syndrome may occur spontaneously before treatment, it usually develops shortly after the initiation of cytotoxic chemotherapy. These metabolites can overwhelm the homeostatic mechanisms with development of hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia. These biological manifestations may lead to clinical manifestations including, acute kidney injury, seizure, or sudden death that require intensive care. Since clinical tumor lysis syndrome is associated with a poor prognosis both prevention of tumor lysis syndrome and prevention of clinical consequences of tumor lysis syndrome are mandatory. The objective of this review is to describe pathophysiological mechanisms, biological and clinical manifestations of tumor Lysis syndrome, and to provide upto-date guidelines to ensure prevention of tumor lysis syndrome. Review of selected studies on tumor lysis syndrome published at the PubMed database www.pubmed.gov during the last 20 years. Additional references were retrieved from the studies initially selected. Tumor lysis syndrome is a frequent and life-threatening complication of the newly diagnosed malignancies. Preventive measures, including hydration, uricolytic agents, eviction of factors predisposing to acute kidney injury and, in the more severe patients, on prophylactic renal replacement therapy, are required to prevent or limit clinical consequences of Tumor lysis syndrome. However optimal timing and modalities of prevention remains unknown and may be modified by the changing spectrum of patients at risk of tumor lysis syndrome. Development and validation of risk based strategies is required to limit the high morbidity and mortality of this complication.
Similar articles
- Tumour lysis syndrome: new therapeutic strategies and classification.
Cairo MS, Bishop M. Cairo MS, et al. Br J Haematol. 2004 Oct;127(1):3-11. doi: 10.1111/j.1365-2141.2004.05094.x. Br J Haematol. 2004. PMID: 15384972 Review. - Oncological emergencies: tumor lysis syndrome.
Sobota J, Püsküllüoglu M, Zygulska AL. Sobota J, et al. Przegl Lek. 2014;71(4):210-4. Przegl Lek. 2014. PMID: 25141580 Review. - An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Mughal TI, Ejaz AA, Foringer JR, Coiffier B. Mughal TI, et al. Cancer Treat Rev. 2010 Apr;36(2):164-76. doi: 10.1016/j.ctrv.2009.11.001. Epub 2009 Dec 23. Cancer Treat Rev. 2010. PMID: 20031331 Review. - Tumour lysis syndrome in haematological malignancies.
van der Hoven B, Thunnissen PL, Sizoo W. van der Hoven B, et al. Neth J Med. 1992 Feb;40(1-2):31-5. Neth J Med. 1992. PMID: 1579184 Review. - [Acute tumor lysis syndrome due to mono-therapy with a corticosteroid in a patient with non-Hodgkin lymphoma].
Wester JP, Breumelhof R, Geers AB, Meuwissen OJ. Wester JP, et al. Ned Tijdschr Geneeskd. 1997 Aug 16;141(33):1621-3. Ned Tijdschr Geneeskd. 1997. PMID: 9543767 Dutch.
Cited by
- Acute Oncologic Complications: Clinical-Therapeutic Management in Critical Care and Emergency Departments.
Gri N, Longhitano Y, Zanza C, Monticone V, Fuschi D, Piccioni A, Bellou A, Esposito C, Ceresa IF, Savioli G. Gri N, et al. Curr Oncol. 2023 Aug 2;30(8):7315-7334. doi: 10.3390/curroncol30080531. Curr Oncol. 2023. PMID: 37623012 Free PMC article. Review.